Structural biology and drug discovery

Current Pharmaceutical Design

Volumn 12, Issue 17, 2006, Pages 2087-2097

  Scapin, Giovanna ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Computational method; De novo ligand generation; Lead optimization; Pentostatin; Src SH2 inhibitor; Virtual screening

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DEAMINASE INHIBITOR; ANTIINFECTIVE AGENT; CYCLIN DEPENDENT KINASE 2 INHIBITOR; ENZYME INHIBITOR; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NUCLEOSIDE DERIVATIVE; PENTOSTATIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN SH2 INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PYRIDOLPYRIMIDINE INHIBITOR; QUINAZOLINONE INHIBITOR; RIBONUCLEASE A INHIBITOR; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; AUTOMATION; BIOINFORMATICS; BIOTECHNOLOGICAL PROCEDURES; COMPUTER AIDED DESIGN; COMPUTER ANALYSIS; COMPUTER MODEL; COMPUTER PROGRAM; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GENOMICS; HAIRY CELL LEUKEMIA; HUMAN; LIGAND BINDING; MACROMOLECULE; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MUTATIONAL ANALYSIS; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DATABASE; PROTEIN DETERMINATION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RELIABILITY; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYNCHROTRON; UNSPECIFIED SIDE EFFECT; VIRTUAL REALITY; X RAY CRYSTALLOGRAPHY;

COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DATABASES, GENETIC; DRUG DESIGN; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTAGENESIS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEINS; STRUCTURAL HOMOLOGY, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745161050     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777585201     Document Type: Review

References (109)

1. Beddell CR, Goodford PJ, Norrington FE, Wilkinson S, Wootton R. Compound designed to fit a site of known structure in human haemoglobin. Br J Pharmacol 1976; 57: 201-209.
2. Goodford PJ. Drug design by the method of receptor fit. J Med Chem 1984; 27: 558-564.
3. Roberts N, Martin J, Kinchington D, Broadhurst A, Craig J, Duncan I, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 243: 358-361.
4. Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, Norbeck D, et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990; 249: 527-533.
5. Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, et al. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994; 37: 3443-3451.
6. van Duin M, Woolson H, Mallinson D, Black D. Genomics in target and drug discovery. Biochem Soc Trans 2003; 31: 429-432.
7. Bredel M, Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 2004; 5: 262-275.
8. Dohrmann CE. Target discovery in metabolic disease. Drug Discovery Today 2004; 9: 785-794.
9. Abola E, Kuhn P, Earnest T, Stevens, RC. Automation of X-ray crystallography. Nat Struct Biol 2000; 7: 983-977.
10. Mueller U, Nyarsik L, Horn M, Rauth H, Przewieslik T, Saenger W, et al. Development of a technology for automation and miniaturization of protein crystallization. Biotech J 2001; 85: 7-14.
11. Muchmore SW, Olson J, Jones R, Pan J, Blum M, Greer J, et al. Automated crystal mounting and data collection for protein crystallography. Structure 2000; 8: R243-R246.
12. Hendrickson WA. Synchrotron crystallography. Trends Biochem Sci 2000; 25: 637-643.
13. Kuhn P, Wilson K, Patch MG, Stevens RC. The genesis of high-throughput structure-based drug discovery using protein crystallography. Current Opin Struct Biol 2002; 6: 704-710.
14. Stout TJ, Foster PG, Matthews DJ. High-throughput structural biology in drug discovery: Protein kinases. Curr Pharm Design 2004; 10: 1069-1082.
15. Tickle I, Sharff A, Vinkovic M, Yon J, Jhoti H. High-throughput protein crystallography and drug discovery. Chem Soc Rev 2004; 33: 558-565.
16. Buchanan SG. Structural genomics: bridging functional genomics and structure-based drug design. Curr Opin Drug Disc Develop 2002; 5: 367-381.
17. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Disc 2002; 1: 727-730.
18. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289: 739-745.
19. Heldwein EE, Macia E, Wang J, Yin HL, Kirchhausen T, Harrison SC. Crystal structure of the clathrin adaptor protein 1 core. Proc Natl Acad Sci USA 2004; 101: 14108-14113.
20. Malinina L, Malakhova ML, Teplov A, Brown RE, Patel DJ. Structural basis for glycosphingolipid transfer specificity. Nature 2004; 430: 1048-1053.
21. Ban N, Nissen P, Hansen J, Moore PB, Steitz, TA. The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science 2000; 289: 905-920.
22. Lundstrom K. Structural genomics on membrane proteins: mini review. Comb Chem High Throughput Screen 2004; 7: 431-439.
23. Walian P, Cross TA, Jap BK. Structural genomics of membrane proteins. Genome Biol 2004; 5: 215.
24. Diller DJ, Li R. Kinases, homology models, and high throughput docking. J Med Chem 2003; 46: 4638-4647.
25. Rowland RS. Using X-ray crystallography in drug discovery. Curr Opin Drug Discov Devel 2002; 5: 613-619.
26. Anderson AC. The Process of Structure-Based Drug Design. Chem Biol 2003; 10: 787-797.
27. Yakunin AF, Yee AA, Savchenko A, Edwards AM, Arrowsmith CH. Structural proteomics: a tool for genome annotation. Curr Opin Chem Biol 2004; 8: 42-48.
28. Orengo CA, Michie AD, Jones S, Jones DT, Swindells MB, Thornton, JM. CATH - a hierarchic classification of protein domain structures. Structure 1997; 5: 1093-1108.
29. Pearl FM, Bennett CF, Bray JE, Harrison AP, Martin N, Shepherd A, et al. The CATH database: an extended protein family resource for structural and functional genomics. Nucleic Acids Res 2003; 31: 452-455.
30. Holm L, Sander C. The FSSP database: fold classification based on structure-structure alignment of proteins. Nucleic Acids Res 1996; 24: 206-209.
31. Dietmann S, Holm L. Identification of homology in protein structure classification. Nat Struct Biol 2001; 8: 953-957.
32. Murzin AG, Brenner SE, Hubbard T, Chothia C. SCOP: a structural classification of proteins database for the investigation of sequences and structuRes J Mol Biol 1995; 247: 536-540.
33. Lo Conte L, Ailey B, Hubbard TJ, Brenner, SE, Murzin AG, Chothia C. SCOP: a structural classification of proteins database. Nucleic Acids Res 2000; 28: 257-259.
34. Jones S, Thornton JM. Searching for functional sites in protein structuRes Curr Opin Chem Biol 2004; 8: 3-7.
35. Schmid MB. Seeing is believing: the impact of structural genomics on antimicrobial drug discovery. Nat Rev Microbiol 2004; 2: 739-746.
36. Golebiowski A, Klopfenstein SR, Portlock DE. Lead compounds discovered from libraries: Part 2. Curr Opin Chem Biol 2003; 7: 308-325.
37. Hertzberg RP, Pope AJ. High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 2000; 4: 445-451.
38. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogeneous leukemia. J Clin Invest 2000; 105: 3-7.
39. Jimonet P, Jager R. Strategies for designing GPCR-focused libraries and screening sets. Curr Opin Drug Discov Devel 2004; 7: 325-333.
40. Lowrie JF, Delisle RK, Hobbs DW, Diller, DJ. The different strategies for designing GPCR and kinase targeted libraries. Comb Chem High Throughput Screen 2004; 7: 495-510.
41. Real E, Rain J-C, Battaglia V, Jallet C, Perrin P, Tordo N., et al. Antiviral drug discovery strategy using combinatorial libraries of structurally constrained peptides. J Virol 2004; 78: 7410-7417.
42. Schnur D, Beno BR, Good A, Tebben A. Approaches to target class combinatorial library design. Methods Mol Biol 2004; 275: 355-378.
43. Wiedemann U, Boisguerin P, Leben R, Leitner D, Krause G, Moelling K, et al. Quantification of PDZ domain specificity, prediction of ligand affinity and rational design of super-binding peptides. J Mol Biol 2004; 343: 703-718.
44. Amtul Z, Rasheed M, Choudhary MI, Rosanna S, Khan KM, and Atta-ur-Rahman. Kinetics of novel competitive inhibitors of urease enzymes by a focused library of oxadiazoles/thiadiazoles and triazoles. Biochem Biophys Res Comm 2004; 319: 1053-1063.
45. Gray NS, Wodicka L, Thunnissen A-MWH, Norman TC, Kwon S, Espinoza FH, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998; 281: 533-538.
46. Honma T, Yoshizumi T, Hashimoto N, Hayashi K, Kawanishi N, Fukasawa K, et al. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J Med Chem 2001; 44: 4628-4640.
47. Laird ER, Blake JF. Structure-based generation of viable leads from small combinatorial libraries. Curr Opin Drug Discov Devel 2004; 7: 354-359.
48. Verdonk ML, Hartshorn MJ. Structure-guided fragment screening for lead discovery. Curr Opin Drug Discov Devel 2004; 7: 404-410.
49. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
50. Shuker SB, Hajduk PJ, Meadows RP, and Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996; 274: 1531-1534.
51. Lesuisse D, Lange G, Deprez P, Benard D, Schoot B, Delettre G, et al. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J Med Chem 2002; 45: 2379-2387.
52. Gill AL, Frederickson M, Cleasby A, Woodhead SJ, Carr MG, Woodhead AJ, et al. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J Med Chem 2005; 48: 414-426.
53. Liu G, Xin Z, Pei Z, Hajduk PJ, Abad-Zapatero C, Hutchins CW, et al. Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. J Med Chem 2003; 46: 4232-4235.
54. Szczepankiewicz BG, Liu G, Hajduk PJ, Abad-Zapatero C, Pei Z, Xin Z, et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc 2003; 125: 4087-4096.
55. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H. Fragment-based lead discovery using X-ray crystallography. J Med Chem 2005; 48: 403-413.
56. Chayen NE. Turning protein crystallisation from an art into a science. Curr Opin Struct Biol 2004; 14: 577-583.
57. Sharff A, Jhoti H. High-throughput crystallography to enhance drug discovery. Curr Opin Chem Biol 2003; 7: 340-345.
58. Hou TJ, Xu XJ. Recent development and application of virtual screening in drug discovery: an overview. Curr Pharm Des 2004; 10: 1011-1033.
59. Jain AN. Virtual screening in lead discovery and optimization. Curr Opin Drug Discov Devel 2004; 7: 396-403.
60. Ji H, Zhang W, Zhang M, Kudo M, Aoyama Y, Yoshida Y, et al. Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. J Med Chem 2003; 46: 474-485.
61. Honma T, Hayashi K, Aoyama T, Hashimoto N, Machida T, Fukasawa K. et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem 2001; 44: 4615-4627.
62. Boehm HJ, Boehringer M, Bur D, Gmuender H, Huber W, Klaus W et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 2000; 43: 2664-2674.
63. Liebeschuetz JW, Jones SD, Morgan PJ, Murray CW, Rimmer AD., Roscoe JM, et al. PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. J Med Chem 2002; 45: 1221-1232.
64. Tan C, Wei L, Ottensmeyer FP, Goldfine I, Maddux BA, Yip CC, et al. Structure-based de novo design of ligands using a three-dimensional model of the insulin receptor. Bioorg Med Chem Lett 2004; 14: 1407-1410.
65. Schmidt JM, Mercure J, Tremblay GB, Page M, Kalbakji A, Feher M. De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor. J Med Chem 2003; 46: 1408-1418.
66. Pierce AC, Rao G, Bemis GW. BREED: Generating Novel Inhibitors through Hybridization of Known Ligands. Application to CDK2, P38, and HIV Protease. J Med Chem 2004; 47: 2768-2775.
67. Murcko M. In: Lipkowitz KB and Boyd DB Eds, Reviews in Computational Chemistry. New York, Wiley, V. C. H. 1997; 1-66.
68. Murcko M. In: Charifson PS Ed, Practical Application of Computer-aided Drug Design. New York, Marcel Dekker 1997; 304-354.
69. Lloyd DG, Buenemann CL, Todorov NP, Manallack DT, Dean PM. Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. J Med Chem 2004; 47: 493-496.
70. Walters WP, Stahl MT, Murcko MA. Virtual screening - an overview. Drug Discov Today 1998; 3: 160-178.
71. Lyne PD. Structure-based virtual screening: an overview. Drug Discov Today 2002; 7: 1047-1055.
72. Xue L, Bajorath J. Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb Chem High Throughput Screen 2000; 3: 363-372.
73. Mason JS, Good AC, Martin EJ. 3-D pharmacophores in drug discovery. Curr Pharm Des 2001; 7: 567-597.
74. Gozalbes R, Doucet JP, Derouin F. Application of topological descriptors in QSAR and drug design: history and new trends. Curr Drug Targets Infect Disord 2002; 2: 93-102.
75. Langer T, Krovat EM. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr Opin Drug Discov Devel 2003; 6: 370-376.
76. Ajay WPW, Murcko MA. Can We Learn To Distinguish between "Drug-like" and "Nondrug-like" Molecules? J Med Chem 1998; 41: 3314-3324.
77. Terasaka T, Kinoshita T, Kuno M, Seki N, Tanaka K, and Nakanishi I. Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. J Med Chem 2004; 47: 3730-3743.
78. Lau CK, Bayly CI, Gauthier JY, Li CS, Therien M, Asante-Appiah E, et al. Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors. Bioorg Med Chem Lett 2004; 14: 1043-1048.
79. Scapin G, Patel SB, Becker JW, Wang Q, Desponts C, Waddleton D, et al. The Structural basis for the selectivity of benzotriazole inhibitors of PTP1B. Biochemistry 2003; 42: 11451-11459.
80. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP binding pocket. Nat Struct Biol 1997; 4: 311-316.
81. Wilson KP, McCaffrey PG, Hsiao K, Pazhanisamy S, Galullo V, Bemis GW, et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997; 4: 423-431.
82. Lisnock JM, Tebben A, Frantz B, O'Neill EA, Croft G, O'Keefe SJ, et al. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 1998; 37: 16573-16581.
83. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 2002; 9: 268-272.
84. Natarajan SR, Wisnoski D, Singh SB, Stelmach JE, O'neill EA, Schwartz CD, et al. p38 MAP kinase inhibitors part 1: Design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold. Bioorg Med Chem Lett 2003; 13: 273-276.
85. Hunt JA, Kallashi F, Ruzek RD, Sinclair PJ, Ita I, Mccormick SX, et al. p38 Inhibitors: Piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones. Bioorg Med Chem Lett 2003; 13: 467-470.
86. Stelmach JE, Liu L, Patel SB, Pivnichny JV, Scapin G, Singh S, et al. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. Bioorg Med Chem Lett 2003; 13: 277-280.
87. Fitzgerald CE, Patel SB, Becker JW, Cameron PM, Zaller D, Pikounis VB, et al. Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat Struct Biol 2003; 10: 764-769.
88. Shoichet BK, Bussiere DE. Macromolecular crystallography and lead discovery: possibilities and limitations. Curr Opin Drug Disc Develop 2000; 3: 408-422.
89. Davis AM, Teague SJ, Kleywegt GJ. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew Chem Int Ed Engl 2003; 42: 2718-2736.
90. Acharya KR, Lloyd MD. The advantages and limitations of protein crystal structures Trends Pharmacol Sci 2005; 26: 10-14.
91. Stubbs MT, Reyda S, Dullweber F, Moller M, Klebe G, Dorsch D, et al. pH-dependent binding modes observed in trypsin crystals: Lessons for structure-based drug design. Chembiochem 2002; 3: 246-249.
92. Hao B, Gong W, Ferguson TK, James CM, Krzycki JA, Chan MK. A New UAG-Encoded Residue in the Structure of a Methanogen Methyltransferase. Science 2002; 296: 1462-1466.
93. Berisio R, Sica F, Lamzin VS, Wilson KS, Zagari A, Mazzarella L. Atomic resolution structures of ribonuclease A at six pH values. Acta Crystallogr D Biol Crystallogr 2002; 58: 441-450.
94. Derewenda ZS. Rational Protein Crystallization by Mutational Surface Engineering. Structure 2004; 12: 529-535.
95. Czepas J, Devedjiev Y, Krowarsch D, Derewenda U, Otlewski J, Derewenda ZS. The impact of Lys -> Arg surface mutations on the crystallization of the globular domain of RhoGDI. Acta Crystallogr D Biol Crystallogr 2004; 60: 275-80.
96. Mateja A, Devedjie Y, Krowarsch D, Longenecker K, Dauter Z, Otlewski J, et al. The impact of Glu -> Ala and Glu -> Asp mutations on the crystallization properties of RhoGDI: the structure of RhoGDI at 1.3 A resolution. Acta Crystallogr D Biol Crystallogr 2002; 58: 1983-91.
97. Nickerson D, Wong L-L, Rao Z. An improved procedure for the preparation of X-ray diffraction-quality crystals of cytochrome P450cam. Acta Crystallogr D Biol Crystallogr 1997; 54: 470-472.
98. Charron C, Kern D, Giege R. Crystal contacts engineering of aspartyl-tRNA synthetase from Thermus thermophilus: effects on crystallizability. Acta Crystallogr D Biol Crystallogr 2002; 58: 1729-1733.
99. Hibi T, Hisada H, Nakatsu T, Kato H, Jun'ichi Oda J. Escherichia coli B-glutamylcysteine synthetase: modification, purification, crystallization and preliminary crystallographic analysis. Acta Crystallogr D Biol Crystallogr 2002; 58: 316-318.
100. Dale GE, Oefner C, D'Arcy A. The protein as a variable in protein crystallization. J Struct Biol 2003; 142: 88-97.
101. McPherson A. Protein crystallization in the structural genomics era. J Struct Funct Genomics 2004; 5: 3-12.
102. Patel SB, Cameron PM, Frantz-Wattley B, O'Neill EA, Becker JW, and Scapin G. Lattice stabilization and enhanced diffraction in human p38[alpha] crystals by protein engineering. Biochim Biophys Acta - Proteins & Proteomics 2004; 1696: 67-73.
103. Chang C-I. Xu B, Akella R, Cobb MH, Goldsmith EJ. Crystal structures of MAP kinase p38 complexed to the docking sites of its nuclear substrate MEF2A and activator MKK3b. Mol Cell 2002; 9: 1241-1249.
104. Scapin G, Patel S, Patel V, Kennedy B, Asante-Appiah E. The structure of apo protein-tyrosine phosphatase 1B C215S mutant: More than just an S -> O change. Protein Sci 2001; 10: 1596-1605.
105. Jackson LK, Baldwin J, Akella R, Goldsmith EJ, Phillips MA. Multiple active site conformations revealed by distant site mutation in ornithine decarboxylase. Biochemistry 2004; 43: 12990-12999.
106. Puius YA, Zhao Y, Sullivan M, Lawrence DS, Almo SC, Zhang ZY. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proc Natl Acad Sci USA 1997; 94: 13420-13425.
107. Sakoff JA, McCluskey A. Protein phosphatase inhibition: structure based design. Towards new therapeutic agents. Curr Pharm Des 2004; 10(10): 1139-59.
108. Stout TJ, Foster PG, Matthews DJ. High-throughput structural biology in drug discovery: protein kinases. Curr Pharm Des 2004; 10(10): 1069-82.
109. Suh KS, Yuspa SH. Intracellular chloride channels: critical mediators of cell viability and potential targets for cancer therapy. Curr Pharm Des 2005; 11(21): 2753-64.